Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14060330 | 0.87 | TSHR (0.56) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL7131786 | 0.86 | TSHR (0.62) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL15686510 | 0.85 | TSHR (0.57) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL496751 | 0.84 | TSHR (0.61) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL6204264 | 0.84 | TSHR (0.53) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL8870409 | 0.83 | TSHR (0.59) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL31435656 | 0.83 | TSHR (0.59) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL8870399 | 0.83 | TSHR (0.59) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL1169876 | 0.83 | TSHR (0.59) | TSHRCYP1A2CYP2C19CYP3A4LMNA | |
| SCHEMBL19220492 | 0.83 | TSHR (0.39) | TSHRCYP1A2CYP2C19CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249675-B | Preparation method of 2-nitro-4-methylsulfonyl benzoic acid | 北京颖泰嘉和生物科技股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-119930484-A | Synthesis method of 4-methylsulfonyl toluene derivative | 辽宁龙田化工科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119552099-A | Green synthesis method of 2-nitro-4-methylsulfonyl benzoic acid | 浙江工业大学 | 2025-03-04 | — | — | CN | disclosed |
| CN-118255699-A | Method for continuously preparing 2-nitro-4-methylsulfonyl benzoic acid | 北京颖泰嘉和生物科技股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-115819297-B | Preparation method of 2-nitro-4-methylsulfonyl benzoic acid | 南京先进生物材料与过程装备研究院有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117715887-A | Preparation method of 2-nitro-4-methylsulfonyl benzoic acid | 加尔达化学有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117447368-A | Catalytic technology for producing 2-nitro-4-methylsulfonyl benzoic acid | 华东理工大学 | 2024-01-26 | — | — | CN | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| CN-117185970-A | Method for continuously preparing 2-nitro-4-methylsulfonyl toluene | 北京颖泰嘉和生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-114249675-B | Preparation method of 2-nitro-4-methylsulfonyl benzoic acid | 北京颖泰嘉和生物科技股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | TSHR 560/4885CYP1A2 16/4885CYP2C19 4/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | TSHR 3945/4885CYP1A2 3280/4885CYP2C19 2625/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | TSHR 1891/4885CYP1A2 8/4885CYP2C19 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.